Xoma | XOMA - Gastos De Venta Y Administración





Gastos De Venta Y Administración Cambio Fecha
AbbVie USD 3.58B 316M 2026-03
Agenus USD 10.56M 13.04M 2025-12
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Ardelyx USD 102.27M 26.35M 2026-03
aTyr Pharma USD 700.63K 81.56M 2026-03
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
Celldex Therapeutics USD 11.45M 3.61M 2026-03
Curis USD 1.34M 3.45M 2025-12
Eli Lilly USD 2.93B 198M 2026-03
Emergent BioSolutions USD 182.8M 82.3M 2023-06
Incyte USD 328.1M 62.31M 2026-03
MacroGenics USD 9.71M 1.77M 2026-03
Novartis USD 3.14B 296M 2026-03
Novartis USD 3.14B 296M 2026-03
Pfizer USD 2.92B 1.16B 2026-03
Prothena USD 12.67M 5.02M 2026-03
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Xoma USD 11M 2.54M 2024-06